JBC Focus on PI3-Kinase with Echelon

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M000142200 on March 30, 2000

J. Biol. Chem., Vol. 275, Issue 23, 17596-17604, June 9, 2000
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
275/23/17596    most recent
M000142200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bremnes, T.
Right arrow Articles by Attramadal, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bremnes, T.
Right arrow Articles by Attramadal, H.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Regulation and Intracellular Trafficking Pathways of the Endothelin Receptors*

Toril BremnesDagger , Joachim D. PaascheDagger , Anja MehlumDagger , Cecilie SandbergDagger , Bjørn Bremnes§, and Håvard AttramadalDagger

From the Dagger  Merck Sharp & Dohme Cardiovascular Research Center and Institute of Surgical Research, University of Oslo, The National Hospital, 0027 Oslo, Norway and the § Department of Biochemistry, The Norwegian Radium Hospital, 0310 Oslo, Norway

Received for publication, January 10, 2000, and in revised form, March 15, 2000

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The effects of endothelin (ET) are mediated via the G protein-coupled receptors ETA and ETB. However, the mechanisms of ET receptor desensitization, internalization, and intracellular trafficking are poorly understood. The aim of the present study was to investigate the molecular mechanisms of ET receptor regulation and to characterize the intracellular pathways of ET-stimulated ETA and ETB receptors. By analysis of ETA and ETB receptor internalization in transfected Chinese hamster ovary cells in the presence of overexpressed beta ARK, beta -arrestin-1, beta -arrestin-2, or dynamin as well as dominant negative mutants of these regulators, we have demonstrated that both ET receptor subtypes follow an arrestin- and dynamin/clathrin-dependent mechanism of internalization. Fluorescence microscopy of Chinese hamster ovary and COS cells expressing green fluorescent protein (GFP)-tagged ET receptors revealed that the ETA and ETB subtypes were targeted to different intracellular routes after ET stimulation. While ETA-GFP followed a recycling pathway and colocalized with transferrin in the pericentriolar recycling compartment, ETB-GFP was targeted to lysosomes after ET-induced internalization. Both receptor subtypes colocalized with Rab5 in classical early endosomes, indicating that this compartment is a common early intermediate for the two ET receptors during intracellular transport. The distinct intracellular routes of ET-stimulated ETA and ETB receptors may explain the persistent signal response through the ETA receptor and the transient response through the ETB receptor. Furthermore, lysosomal targeting of the ETB receptor could serve as a biochemical mechanism for clearance of plasma endothelin via this subtype.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The multiple physiological effects of the vasoactive peptide hormone endothelin (ET)1 (1) are mediated via the G protein-coupled receptors (GPCRs) ETA and ETB (2). ET-1 acts directly on ETA receptors expressed on vascular smooth muscle cells to mediate a long lasting vasoconstrictive response. The prolonged response through agonist-stimulated ETA receptors has also been demonstrated in cultured cells expressing this receptor (3). Although the ETB receptor may also mediate vasoconstriction (4, 5), this subtype, which is primarily situated at the plasma membrane of endothelial cells, is first of all considered to cause transient NO-mediated vasodilatation (6).

Circulating ET-1 is rapidly removed from the plasma, and current evidence suggests that the ETB receptor is important for clearance of plasma ET-1 both under normal conditions (7, 8) and in pathological conditions with increased plasma levels of ET-1 (9). The mechanism of ETB receptor-mediated clearance of ET-1 is not known, but one hypothesis is that receptor-bound ET-1 is targeted to degradation in the cell.

The general model for regulation of GPCR desensitization and internalization is primarily based on studies of the prototypic beta 2-adrenergic receptor (10-15). According to this model, agonist-activated receptors are phosphorylated by GPCR kinases (GRKs), followed by binding of arrestin and initiation of receptor internalization through a clathrin/dynamin-dependent mechanism (16-18). Both the ETA and the ETB receptors have been shown to undergo rapid desensitization (19, 20) and to internalize with similar kinetics (3, 21) in transfected cell models. However, neither the molecular mechanisms of ETA and ETB receptor regulation nor their intracellular trafficking pathways are known. Addressing these issues may not only elucidate the mechanisms of ET receptor regulation but may also provide the molecular basis for the distinct physiological responses mediated by the two receptors.

We have used transfected Chinese hamster ovary (CHO) and COS cells as model systems for studying ET receptor internalization and intracellular trafficking. To facilitate the latter, we have constructed chimeric ET receptors with a C-terminal fusion of green fluorescent protein (GFP). The chimeric ET receptors were found to have similar functional properties as their wild type counterparts, making them appropriate tools for this study. We found that although both the ETA and the ETB receptors utilize an arrestin and dynamin/clathrin-dependent mechanism of internalization, they follow different intracellular pathways upon ET stimulation. Based on our data, we suggest that different intracellular trafficking routes may be an important mechanism underlying the distinct physiological responses mediated by the ETA and ETB receptors.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Plasmid Constructs-- The human ETA and ETB receptors in pME18sf (22) were provided by Prof. T. Masaki (Kyoto University, Japan). An EcoRI-NotI fragment of pME18sf-ETA was subcloned into pcDNA1 for expression in CHO cells. For subcloning of the ETB receptor, PCR-directed mutagenesis was used to introduce a HindIII site in front of the start codon, followed by cloning of the fragments HindIII-EcoRV and EcoRV-XbaI into pcDNA1. The cDNAs of hemagglutinin (HA) epitope-tagged dynamin WT and dynamin K44A mutant (23) in pRK5 were gifts from Dr. C. van Koppen (University of Essen, Germany). Rat beta -arrestin-1 and beta -arrestin-2 were in pCMV5 (24). Their respective mutants V53D and V54D in pcDNA1 were from Dr. M. G. Caron (Duke University, Durham, NC). Rat beta ARK1 in pCMV5 and beta ARK1-CT in pRK5 were gifts from Dr. R. J. Lefkowitz and Dr. W. Koch, respectively (Duke University). MycRab5 Q79L in pcDNA1 and the human transferrin receptor (TfR) in pGEM1-T7 were from Dr. H. Stenmark (the Norwegian Radium Hospital, Oslo). An EcoRI digest of pGEM1-hTfR was subcloned into pcDNA1 for expression in CHO cells.

Construction of ETA-GFP and ETB-GFP Chimeric Receptors-- pEGFPN1 (CLONTECH), an expression vector containing the coding sequence of a modified form of GFP from Aequorea victoria was chosen for cloning and expression of the ET receptor fusion proteins. For construction of ETA-GFP, PCR-directed mutagenesis was performed on the template pBS-ETA using the oligonucleotide primers 5'-ctaagcaatcatgtggatg-3' and 5'-gcggatcccggttcatgctgtccttatggctgc-3' to remove the stop codon of ETA and introduce a BamHI restriction site. The HindIII-KpnI and KpnI-BamHI fragments of ETA were subsequently inserted into pEGFPN1 to create a receptor fusion protein with GFP linked to the C-terminal cytoplasmic tail. Similarly, for construction of ETB-GFP, PCR was performed on the template pcDNA1-ETB with the primers 5'-gatcccaatagatgtgaac-3'and 5'-cgcggatcccgagatgagctgtatttattactgg-3' to remove the stop codon and introduce a BamHI site. The HindIII-BamHI fragment of ETB was subsequently cloned into the pEGFPN1 expression vector.

Cell Lines and Transfections-- CHO K1 cells (ATCC no. CCL-61) were maintained in Ham's F-12 Kaighn's modified medium (Life Technologies, Inc.) supplemented with 10% fetal bovine serum (Bio Whittaker) and 50 µg/ml garamycin in a humidified atmosphere containing 5% CO2 at 37 °C. COS-7 cells (ATCC no. CRL-1651) were propagated in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum and garamycin as above. Cells were grown to 40-60% confluency in 35-mm wells before transient transfection using LipofectAMINE reagent (Life Technologies) according to the manufacturer's instructions. For immunofluorescence experiments, cells were plated onto glass coverslips in 24-well plates before LipofectAMINE transfection. Rab5 Q79L was expressed in CHO cells using the vaccinia T7 expression system as described by Stenmark et al. (25).

Kinetics of 125I-ET-1 Internalization-- Internalization of ETA and ETB receptors was determined using 125I-ET-1 (Amersham Pharmacia Biotech). Twenty-four hours after transfection, the cells were placed on ice, washed, and preincubated in binding buffer (Hanks' balanced salt solution with 20 mM Hepes, pH 7.4, 0.2% BSA, and 0.1% glucose) before binding of 50 pM 125I-ET-1 in binding buffer for 3 h at 4 °C. The cells were washed extensively in ice-cold PBS to remove unbound radioligand before incubation in prewarmed binding buffer at 37 °C for various time points. The cells were subsequently treated for 2 × 10 min at 4 °C with 0.5 M acetic acid, 0.15 M NaCl, pH 2.5 (ETA), or 50 mM glycine-HCl, 0.5 M NaCl, pH 2.5 (ETB) to strip off surface-bound radioligand. Acid-stripped cells were then lysed for 10 min in M NaOH before the fraction of surface-bound ET-1 in the acid wash and the fraction of internalized ET-1 in the lysate were determined by gamma -spectrometry. Internalized receptor was calculated as the fraction of radioactivity not associated with the cell surface after acid wash. Nonspecific binding was determined using excess of unlabeled ET-1 (Peninsula Laboratories).

Western Blot Analysis-- To verify the expression of the different GPCR regulators and their respective mutants, we performed Western blot analysis of samples from the transiently transfected CHO cells. Protein samples were prepared by harvesting cells in 10 mM Tris-HCl, pH 7.4, 1% SDS, 1 mM Na3VO4. 25 µg of protein was loaded per well for SDS-polyacrylamide gel electrophoresis followed by electroblotting onto polyvinylidene difluoride membranes. For beta ARK1 and beta ARK1-CT, we used TBS (50 mM Tris-HCl, pH 8.0, 100 mM NaCl) with 0.1% Tween 20, 2.5% dry milk powder, and 2.5% BSA for blocking and antibody incubations. Primary antibody was affinity-purified polyclonal anti-GRK2 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) used at 1:300. As secondary antibody, we used horseradish peroxidase-conjugated donkey anti-rabbit IgG (Amersham Pharmcia Biotech) diluted at 1:3000. For beta -arrestins and dynamin, we used PBS with 0.05% Tween 20, 2.5% dry milk powder, and 2.5% BSA for blocking and antibody incubations. To detect beta -arrestins, we used polyclonal antisera raised against the respective proteins (24) and horseradish peroxidase-conjugated donkey anti-rabbit secondary antibody. Hemagglutinin-tagged dynamin was detected with a monoclonal anti-HA (12CA5) antibody (Babco) diluted 1:1000 and a horseradish peroxidase-conjugated sheep anti-mouse Ig secondary antibody (1:3000). The blots were developed using enhanced chemiluminescence (ECL) as recommended by the manufacturer (Amersham Pharmacia Biotech).

Phosphorylation of GFP Fusion Proteins-- Transiently transfected CHO cells (35-mm wells) expressing ETA-GFP or ETB-GFP with or without coexpression of beta ARK1 or beta ARK2 were labeled with 500 µCi/well of [32Pi] (NEN Life Science Products) in phosphate-free Dulbecco's modified Eagle's medium for 1 h at 37 °C. To promote receptor activation/phosphorylation, the cells were subsequently incubated with ET-1 (1 µM) for 10 min. After ET-1 stimulation, the cells were rapidly chilled on ice, washed twice in PBS, and lysed for 30 min in ice-cold radioimmune precipitation buffer containing protease inhibitors (150 mM NaCl, 50 mM Tris-HCl, pH 8.0, 5 mM EDTA, 1% Nonidet P40, 0.5% deoxycholate, 0.1% SDS, 10 mM NaF, 10 mM Na2 pyrophosphate, and protease inhibitors (0.1 mM phenylmethylsulfonyl fluoride, 10 µg/ml benzamidine, 10 µg/ml leupeptin, 5 µg/ml aprotinin, and 1 µg/ml pepstatin A)). Cell lysates were cleared by centrifugation for 10 min at 10,000 × g (4 °C), and immunoprecipitation of labeled receptors was performed using a rabbit polyclonal peptide antibody against GFP (CLONTECH) and protein A-agarose (Upstate Biotechnology Inc.). Beads with antibody-antigen complexes were washed three times in radioimmune precipitation buffer and subsequently denatured at 65 °C in 2× SDS loading buffer (Laemmli) containing 5% urea and 5% beta -mercaptoethanol. Immunoprecipitated proteins were separated by SDS-polyacrylamide gel electrophoresis followed by autoradiography on phosphor screens and PhosphorImager analysis (Molecular Dynamics, Inc., Sunnyvale, CA).

Phosphoinositide Hydrolysis-- Twenty-four hours after transfection, CHO cells (35-mm wells) were labeled with 2 µCi/ml myo-[3H]inositol in Dulbecco's modified Eagle's medium without inositol (Life Technologies) for 24 h. The cells were subsequently washed and treated with 20 mM LiCl in medium with or without 0.1 µM ET-1 for different time points, with six parallels at each time point. The reactions were terminated by adding 1 ml/well of 0.4 M perchloric acid for 5-10 min at room temperature. The samples (0.8 ml) were neutralized with 0.4 ml of 0.72 M KOH, 0.6 M KHCO3 and centrifuged for 15 min at 3000 rpm. The supernatants were diluted in distilled H2O (1:4), and total inositol phosphates were separated by anion exchange chromatography on Dowex AG1-8x columns (Bio-Rad). The columns were washed twice with 10 ml of distilled H2O to remove free inositol, followed by elution of total inositol phosphates with 7.5 ml of 1 M ammonium formate, 0.1 M formic acid and determination of 3H by liquid scintillation counting.

Radioligand Binding-- Radioligand binding was performed on membrane preparations according to Elshourbagy et al. (26) with the modifications outlined below. CHO cells transiently transfected with receptor were washed in ice-cold PBS and harvested in 25 mM Tris-HCl, 2 mM EDTA, pH 8.0, containing protease inhibitors (30 µg/ml benzamidine, 100 µM phenylmethylsulfonyl fluoride). The cells were homogenized on ice using a Dounce glass homogenizer, followed by centrifugation at 50,000 × g for 15 min. The membrane pellets were resuspended in 25 mM Tris-HCl, pH 7.5, 2 mM EDTA, 100 mM NaCl, 1 mg/ml BSA, and protease inhibitors as above, and saturation binding analysis was performed for 1 h at 37 °C using 2-1000 pM 125I-ET-1 in the absence (total binding) or presence (nonspecific binding) of a 100-fold excess of unlabeled ET-1. For the binding experiments, we used 1 µg of membrane protein in a total volume of 75 µl per sample. The samples were filtered through Whatman GF/C filters presoaked with 0.05% BSA to remove unbound ligand. After three washes in 0.5 M NaCl, the filters were subjected to gamma -spectrometric analysis.

Analysis of Internalized ETA-GFP and ETB-GFP by Fluoresence Microscopy-- For analysis of ET receptor trafficking, transfected cells grown on glass coverslips were placed on ice, washed, and preincubated for 10 min with Hanks' balanced salt solution-Hepes before binding of 0.4 µM ET-1 in binding buffer (Hanks' balanced salt solution-Hepes with 0.2% BSA and 0.1% glucose) for 1 h at 4 °C. Unbound ligand was removed by washing in Hanks' balanced salt solution-Hepes, and the cells were subsequently incubated at 37 °C for various periods of time. The cells were fixed in 4% paraformaldehyde before mounting onto object glasses using Mowiol (Hoechst). The specimens were analyzed using either a Zeiss Axiovert-100 fluorescence microscope or a Leica TCS laser-scanning microscope with a 100 × 1.3 oil immersion objective. Images were processed and overlaid using Photoshop 4.0 and the Metamorph Imaging System.

Uptake of Fluorescent Probes and Staining of Intracellular Antigens for Fluorescence Microscopy-- For the transferrin (Tf) uptake experiments, cells were cotransfected with ET receptor and the human TfR. Cells were pretreated with 10 µg/ml cycloheximide for 30 min before ET-1 binding was performed as described above. During ET-1 internalization at 37 °C, tetramethylrhodamine-conjugated Tf (Molecular Probes, Inc., Eugene, OR) was added to the cells in binding buffer at a concentration of 25 µg/ml for labeling of the pericentriolar recycling compartment. The cells were washed in ice-cold PBS before fixation in 4% paraformaldehyde and mounting onto object glasses for fluorescence microscopy analysis.

Labeling of lysosomes in CHO cells was done overnight with 0.2 mg/ml Texas Red-conjugated dextran (Molecular Probes) followed by a 2-h chase period at 37 °C to wash the probe out of early and late endosomes. To analyze receptor trafficking in this experiment, ET-1 was internalized for various periods of time during the 2-h chase period. The cells were fixed and mounted as described above and subjected to fluorescence microscopy.

For staining of intracellular antigens, the cells were permeabilized in PBS containing 0.1% Triton X-100 after paraformaldehyde fixation. Free aldehyde groups were quenched by adding a few drops of 1 M glycine, pH 8.5, to the PBS wash prior to the permeabilization step. 10% fetal bovine serum in PBS was added for 5 min at room temperature for blocking before antibody incubation. Primary and secondary antibodies were diluted in PBS to a concentration recommended by the manufacturer or as experienced to give optimal results. Between antibody incubations, the cells were extensively washed in PBS. Immunofluorescence staining of endogenous beta COP in CHO cells was done using a rabbit antiserum and a Texas Red-conjugated goat anti-rabbit secondary antibody (Southern Biotechnology). Late endosomes and lysosomes in COS cells were visualized using a rabbit antiserum against human LAMP-2 and an Alexa594-conjugated goat anti-rabbit secondary antibody (Molecular Probes). Staining of MycRab5 Q79L expressed using the vaccinia T7 system was performed using a mouse anti-Myc antibody followed by a rhodamine-labeled goat anti-mouse secondary antibody (both from Dr. H. Stenmark, the Norwegian Radium Hospital, Oslo).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Mechanisms of ETA and ETB Receptor Internalization in CHO Cells-- To investigate the effects of different regulators of GPCR on ET receptor internalization, CHO cells were transiently transfected with ETA or ETB receptors alone or together with wild type or mutant forms of beta ARK1 (GRK2), beta -arrestin-1, beta -arrestin-2, and dynamin. Receptor internalization was determined by 125I-ET-1 uptake as described under "Experimental Procedures." Internalized receptor at each time point was calculated as the fraction of radioactivity left after removing surface-bound radioligand with low pH wash. ETA and ETB receptors were both rapidly internalized upon agonist stimulation, reaching 25% within 10 min (Fig. 1), which is consistent with previous reports on ET receptor internalization (3, 21).


View larger version (38K):
[in this window]
[in a new window]
 
Fig. 1.   Effects of wild type and mutant beta ARK1, beta -arrestins, and dynamin on ET receptor internalization. A-H demonstrate internalization kinetics of the ETA receptor (left panels) or ETB receptor (right panels) in CHO cells cotransfected with various regulator proteins as indicated below. Expression of regulator proteins was determined by Western blot analysis as described under "Experimental Procedures." 125I-ET-1 was bound to the transfected cells for 3 h at 4 °C, and unbound ligand was removed by extensive washing. Internalization was performed at 37 °C for different periods of time. At each time point % internalized was calculated as the fraction of radioactivity not associated with the cell surface (acid-resistant activity). Data are mean ± S.D. of three parallel wells and representative of at least three separate experiments. A and B, CHO cells transfected with ET receptor alone () and ET receptor together with beta ARK1 WT (black-triangle) or beta ARK1-CT (black-square). C-F, CHO cells transfected with ET receptor alone () and ET receptor together with beta -arrestin-1 (black-square, C and D), beta -arrestin-2 (black-triangle, C and D), beta -arrestin-1 V53D (black-square, E and F), or beta -arrestin-2 V54D (black-triangle, E and F). G and H, CHO cells transfected with ET receptor alone () and ET receptor together with dynamin WT (black-triangle) or dynamin K44A (black-square).

beta ARK1-CT, a C-terminal fragment of beta ARK1 containing a Gbeta gamma binding domain (pleckstrin homology domain) (27), was cotransfected with the ET receptors to competitively inhibit the actions of endogenous beta ARK. We found that beta ARK1-CT significantly decreased the rate of ETA receptor internalization (Fig. 1A). No effect was observed on internalization of the ETB subtype in this experimental condition (Fig. 1B), although a small inhibition was discernible at higher levels of beta ARK1-CT overexpression (not shown). Coexpression of beta ARK1 wild type had no effect on the internalization kinetics of any of the receptor subtypes (Fig. 1, A and B). However, as shown in the Western blots of Fig. 1, nontransfected CHO cells also express significant amounts of beta ARK1.

beta -Arrestin-1 and beta -arrestin-2 are nonvisual arrestins shown to interdict signaling through GPCRs phosphorylated by GRK (24). Arrestin subsequently targets the receptor to clathrin-mediated endocytosis by binding to the clathrin heavy chain and the beta -adaptin subunit of the AP-2 adaptor (15, 28). As shown in Fig. 1, C and D, internalization of both ET receptor subtypes increased when overexpressing the wild type beta -arrestin-1 and beta -arrestin-2. The effect appeared to be more pronounced on internalization of the ETA receptor than the ETB receptor. This observation was substantiated by ET receptor internalization experiments in CHO cells where transfection of increasing amounts of beta -arrestin-1 or beta -arrestin-2 cDNA was associated with smaller increments of internalization of ETB than of ETA (data not shown). Nevertheless, these results show that both receptors are recognized by arrestins and can be recruited to an arrestin-mediated pathway of internalization. beta -Arrestin-1 V53D and beta -arrestin-2 V54D are dominant negative mutants of beta -arrestin-1 and beta -arrestin-2, respectively, which competitively inhibit endogenous arrestin binding to clathrin (14). When the V53D and V54D mutants were cotransfected with the ET receptors in CHO cells, the internalization rate was significantly reduced for both receptor subtypes (Fig. 1, E and F), demonstrating that endogenous arrestins of the CHO cells are involved in regulation of the transfected ET receptors.

Cotransfection of the GTPase-deficient mutant dynamin K44A (23, 29) substantially inhibited internalization of the ETA and ETB receptors, suggesting that both receptors are subjected to endocytosis through clathrin-coated pits (Fig. 1, G and H). As shown, overexpression of wild type dynamin did not affect ET receptor internalization. Impaired endocytosis of both ET receptor subtypes was also observed after incubation in hyperosmotic sucrose and upon potassium depletion (not shown), i.e. methods demonstrated to inhibit clathrin-mediated endocytosis (30, 31). Taken together, our results implicate a role for arrestins and a dynamin/clathrin-dependent pathway in regulation of ET receptor endocytosis.

Functional Characteristics of the ETA-GFP and ETB-GFP Fusion Proteins-- Redistribution of ET receptors from the plasma membrane to intracellular locations has previously been observed (21, 32), but neither the receptor-containing compartments nor the intracellular trafficking pathways of the receptors have been characterized. To delineate the intracellular trafficking pathways of the ETA and ETB receptors, we employed ET receptor-GFP fusion proteins for visualization of receptors during endocytosis. Chimeric ETA and ETB receptors with GFP fused to the cytoplasmic tail were constructed as described under "Experimental Procedures." Radioligand binding studies of membrane preparations from CHO cells transiently transfected with ETA-GFP or ETB-GFP demonstrated pharmacological properties very similar to the wild type receptors (Table I). Furthermore, internalization of 125I-ET-1 in CHO cells expressing ETA-GFP or ETB-GFP showed that both subtypes were rapidly internalized with kinetics similar to the wild type ETA and ETB receptors (Fig. 2, A and B). The capacity of ETA-GFP and ETB-GFP to mediate ET-1-induced phosphatidyl inositol hydrolysis and inositol phosphate accumulation was also examined, and as shown in Fig. 2, C and D, the chimeric receptors displayed similar efficacies as compared with their wild type counterparts.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Radioligand binding characteristics of wild type and chimeric ET receptors
The properties of ET-1 binding, including the number of binding sites, were determined in CHO cells transiently transfected with ETA WT, ETA-GFP, ETB WT, or ETB-GFP receptors. Binding of 125I-ET-1 was performed on membranes as described under "Experimental Procedures" to determine the equilibrium dissociation constants (Kd) and the maximal binding (Bmax) for the different receptors. All data represent a mean of three parallels, presented with 95% confidence intervals (GraphPad Prism).


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 2.   Functional characteristics of chimeric ETA-GFP and ETB-GFP receptors expressed in CHO cells. Upper panels, internalization kinetics of 125I-ET-1 in CHO cells transiently transfected with wild type ET receptors or chimeric receptors with C-terminal fusion of GFP. A, internalization of ETA WT receptor () compared with ETA-GFP (black-triangle); B, internalization of ETB WT receptor () compared with ETB-GFP (black-triangle). 125I-ET-1 uptake was performed as described in the legend to Fig. 1 and under "Experimental Procedures." As shown, the internalization patterns were similar for the GFP-tagged and the wild type ET receptors. Lower panels, C, inositol phosphate accumulation in CHO cells transiently transfected with ETA WT receptor (, ET-1, 0.1 µM; open circle , basal) or ETA-GFP (black-triangle, ET-1, 0.1 µM; triangle , basal). diamond , untransfected cells stimulated with ET-1 (0.1 µM). D, inositol phosphate accumulation in CHO cells transfected with ETB WT receptor (, ET-1, 0.1 µM; open circle , basal) or ETB-GFP (black-triangle, ET-1, 0.1 µM; triangle , basal). diamond , untransfected cells, as in C. Cells were labeled with myo-[3H]inositol as described under "Experimental Procedures" and incubated with LiCl in the presence or absence of ET-1 (0.1 µM) for the time points indicated. Total inositol phosphates were separated by ion exchange chromatography using Dowex AG1-8x and determined by liquid scintillation counting. As shown, the chimeric ET receptors showed the same pattern of inositol phosphate accumulation as their wild type counterparts.

To investigate the ability of ETA-GFP and ETB-GFP to undergo agonist-induced phosphorylation, we performed whole cell phosphorylation assays. Transfected CHO cells metabolically labeled with inorganic phosphate, 32Pi, were incubated for 10 min in the absence or presence of 1 µM ET-1. Immunoprecipitation of the receptors using an antibody directed against GFP was followed by SDS-polyacrylamide gel electrophoresis and detection of phosphorylated receptors by laser scan PhosphorImager analysis as described under "Experimental Procedures." As shown in Fig. 3, phosphorylation of both ETA-GFP (migrating at Mr 80,000-110,000) and ETB-GFP (migrating at Mr 70,000-85,000) was induced by ET-1 stimulation and could be detected both in the absence and presence of coexpressed beta ARK1 or beta ARK2. Two distinct bands underwent significant agonist-dependent phosphorylation both in ETA- GFP- and ETB-GFP-transfected cells in accordance with previous findings for wild type ET receptors (20). Altogether, our results show that attachment of GFP to the cytoplasmic tail of the ET receptors does not alter the functional characteristics of the receptors.


View larger version (55K):
[in this window]
[in a new window]
 
Fig. 3.   ET-1 induced phosphorylation of ETA-GFP and ETB-GFP. CHO cells transfected with chimeric ETA-GFP (A) or ETB-GFP (B) alone or together with beta ARK1 (GRK2) or beta ARK2 (GRK3) were metabolically labeled with 32Pi and incubated with or without ET-1 (1 µM) for 10 min as described under "Experimental Procedures." Cell lysates were prepared in radioimmune precipitation buffer, and immunoprecipitation of labeled receptors was performed with a polyclonal peptide antibody directed against GFP. After SDS-polyacrylamide gel electrophoresis, phosphorylated receptors were detected by autoradiography and PhosphorImager analysis. The arrows indicate the phosphorylated receptor bands. Molecular mass markers (83 and 62 kDa) are indicated at the left. The autoradiograms are representative of three independent experiments.

Characterization of the Intracellular Trafficking Pathways of ETA-GFP and ETB-GFP-- ETA-GFP and ETB-GFP were transiently transfected into CHO cells to investigate the intracellular routes of the receptors after agonist stimulation. In the absence of agonist, both receptors were localized at the plasma membrane (Fig. 4, A and C). To study the intracellular ET receptor trafficking pathways, CHO cells were incubated with ET-1 (0.4 µM) for 1 h at 4 °C. Unbound ligand was removed by extensive washing, and internalization of the receptors was subsequently studied at 37 °C for different periods of time. Since endocytosis does not occur at 4 °C, receptor internalization is synchronized once the medium is changed to 37 °C. Within a few minutes, both ETA-GFP and ETB-GFP could be detected in intracellular compartments. As shown by immunofluorescence microscopy, strikingly different patterns were observed for the two receptor subtypes. While the ETB receptor was localized to punctate endosome-like structures throughout the cytoplasm 15 min after initiation of internalization, the ETA receptor was found to accumulate in a distinct spotlike structure near the nucleus after 15 min (Fig. 4, B and D). The perinuclear localization of ETA-GFP is typical for the pericentriolar recycling compartment, a tightly clustered accumulation of tubules and vesicles located near the centrioles and the Golgi apparatus (33), which serves as a compartment for controlling recycling of membrane proteins (34). To investigate the nature of the compartment containing ETA-GFP, CHO cells transfected with ETA-GFP were stained for immunofluorescence using an antiserum against beta COP, a subunit of the Golgi-stack coatomer complex (35), and a Texas Red-conjugated secondary antibody after 15 min of ET-mediated receptor internalization. Cycloheximide was included during the incubations to prevent accumulation of newly synthesized ETA-GFP in the Golgi apparatus. As shown in Fig. 5, the red fluorescent beta COP staining (Fig. 5B) was distinct from the intracellular green fluorescence representing ETA-GFP (Fig. 5A), since no yellow color due to colocalization could be seen in the overlaid pictures (Fig. 5C). Repeated analysis always demonstrated that the perinuclear ETA-GFP-containing compartment was close to, but not overlapping with, the Golgi stacks.


View larger version (31K):
[in this window]
[in a new window]
 
Fig. 4.   ET-1-induced internalization of ETA-GFP and ETB-GFP in CHO cells. CHO cells on cover glasses were transiently transfected with ETA-GFP (A and B) or ETB-GFP (C and D) and visualized by fluorescence microscopy either untreated (A and C) or 15 min after the initiation of ET-1 internalization (B and D). ET-1 (0.4 µM) was bound to the cells for 1 h (4 °C), and internalization was subsequently performed at 37 °C as described under "Experimental Procedures." After internalization, cells were fixed in paraformaldehyde at 4 °C and investigated by confocal laser-scanning microscopy. Note that ETA-GFP entered a perinuclear compartment after internalization (B), whereas ETB-GFP entered punctate endosome-like structures throughout the cytoplasm (D).


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 5.   Localization of ETA-GFP but not ETB-GFP to the pericentriolar recycling compartment in CHO cells. Upper panels, A-C, after binding at 4 °C, ET-1 was internalized at 37 °C for 15 min in CHO cells expressing ETA-GFP. After paraformaldehyde fixation and permeabilization in 0.1% Triton X-100, Golgi stacks were visualized by staining with an anti-beta COP antiserum followed by a Texas Red-conjugated goat anti-rabbit secondary antibody. The overlay (C) shows no colocalization between ETA-GFP and beta COP. Middle and lower panels, D-I, ETA-GFP (D-F) or ETB-GFP (G-I) was expressed in CHO cells together with the TfR. At the start of the 15-min ET-1 internalization period, Rh-Tf was added to the cells for labeling of the pericentriolar recycling compartment. The overlays show that ETA-GFP (F) but not ETB-GFP (I) colocalized with Rh-Tf in the recycling compartment.

At steady state, transferrin has been shown to accumulate in the recycling compartment, since the rate-limiting step in recycling is transport from this location (36). To investigate to what extent the perinuclear compartment containing ETA-GFP overlapped with the recycling compartment, tetramethylrhodamine-labeled transferrin (Rh-Tf) was internalized into CHO cells cotransfected with ETA-GFP and TfR. After 15 min of ET-mediated internalization in the presence of Rh-Tf, we found extensive colocalization of ETA-GFP and Rh-Tf in the pericentriolar recycling compartment (Fig. 5, middle panels). ETA-GFP was observed intracellularly for up to 30 min after the initiation of internalization and subsequently reappeared at the plasma membrane (see below). These data indicate that the recycling pathway is the dominant transport route of agonist-stimulated ETA receptors in CHO cells.

When CHO cells cotransfected with ETB-GFP and TfR were investigated, we could not detect ETB-GFP in the recycling compartment. Fig. 5 (lower panels) shows ETB-GFP after 15 min of ET-mediated internalization in the presence of Rh-Tf. The spread vesicular structures containing ETB-GFP do not overlap with the central spot representing the Tf-containing recycling compartment, indicating that the ETB receptor follows another transport pathway in the cell. To investigate whether ETB receptors were transported to lysosomes for degradation, we studied ETB receptor internalization in cells where the lysosomal compartments had been labeled with red fluorescent dextran as described under "Experimental Procedures." After 15 min of internalization, there was no significant overlap between the ETB-containing vesicles and the dextran-labeled lysosomes (Fig. 6, upper panels), but after 90 min (middle panels) the vesicular pattern overlapped extensively (see Fig. 6C, overlay). These findings suggest a degradative transport pathway for the ETB-receptor, which is also consistent with our observation that ETB-GFP did not reappear at the plasma membrane in the presence of cycloheximide. Conversely, ETA-GFP did not colocalize with lysosomes after prolonged ET-mediated internalization, but it was found to recycle back to the plasma membrane independently of cycloheximide (Fig. 6, lower panels). The intracellular trafficking pathways of ETA-GFP and ETB-GFP were also analyzed in COS cells, where the same characteristic differences in intracellular routing were observed. As shown in Fig. 7, ETA-GFP colocalized with transferrin in recycling endosomes (upper panels), whereas ETB-GFP was found to enter LAMP-2 positive late endosomes and lysosomes upon prolonged periods of internalization (middle and lower panels).


View larger version (31K):
[in this window]
[in a new window]
 
Fig. 6.   Lysosomal transport of ETB-GFP and recycling of ETA-GFP. CHO cells expressing ETB-GFP (upper and middle panels) or ETA-GFP (lower panels) were incubated overnight with Texas Red-conjugated dextran (0.2 mg/ml) to label the lysosomal compartments. A 2-h chase without dextran was subsequently performed in order to wash the probe out of early and late endosomes. During the same time span, ET-1 was internalized for different time points as described under "Experimental Procedures" before paraformaldehyde fixation and fluorescence microscopy. ETB-GFP colocalized with dextran-Texas Red-labeled lysosomes after 90 min (middle panels; F is overlay) but not after 15 min (upper panels; C is overlay) of ET-1 internalization. ETA-GFP did not colocalize with lysosomes but reappeared at the plasma membrane after 90 min of ET-1 internalization (lower panels). Incubations were performed in the presence of 10 µM cycloheximide to block de novo synthesis of ET receptors.


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 7.   Intracellular trafficking of ETA-GFP and ETB-GFP in COS cells. Upper panels, A-C, after binding at 4 °C, ET-1 was internalized at 37 °C for 15 min in COS cells expressing ETA-GFP as described under "Experimental Procedures." At the start of the 15-min internalization period, Rh-Tf was added to the cells for labeling of the recycling compartment (COS cells express high levels of endogenous transferrin receptor). The overlay (C) shows colocalization of ETA-GFP and Rh-Tf in the recycling compartment. Middle and lower panels, D-I, ET-1 was bound at 4 °C and internalized at 37 °C for 10 min (middle panels, D-F) or 60 min (lower panels, G-I) in COS cells expressing ETB-GFP. After paraformaldehyde fixation and permeabilization in 0.1% Triton X-100, late endosomes and lysosomes were identified by immunostaining with a rabbit anti-human LAMP-2 antiserum and an Alexa594-conjugated goat anti-rabbit secondary antibody. As shown, ETB-GFP did not overlap with LAMP-2-positive compartments after 10 min of internalization (middle panels; F is overlay). However, distinct overlapping vesicles were identified after 60 min of internalization (lower panels; I is overlay).

Colocalization of ETA-GFP and ETB-GFP with Rab5 in Early Endosomes-- Different members of the Rab family of small GTPases have been shown to regulate distinct transport steps in eucaryotic cells (37). Rab5 is localized to early endosomes and is a rate-limiting component in membrane docking and fusion in the early endocytic pathway (38). Rab5 Q79L is a GTPase-deficient mutant of Rab5 shown to increase homotypic fusion events between early endosomes and retard transport out of these compartments (39). When ETA-GFP and ETB-GFP were expressed together with Rab5 Q79L in CHO cells, both receptors could be detected in early endosomes (Fig. 8, A-F). This experiment demonstrates that the intracellular transport routes of both ETA-GFP and ETB-GFP go through classical early endosomes before they separate into the recycling pathway and the degradative pathway, respectively.


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 8.   Colocalization of ETA-GFP and ETB-GFP with Rab5 in early endosomes. ETA-GFP (upper panels) or ETB-GFP (lower panels) was expressed together with MycRab5 Q79L in CHO cells using T7 vaccinia transfection. Five hours after transfection, ET-1 was bound to the cells at 4 °C and subsequently internalized for 30 min at 37 °C. The cells were fixed in paraformaldehyde and permeabilized with 0.1% Triton X-100. Overexpressed MycRab5 Q79L was identified by immunostaining with a mouse monoclonal anti-Myc antibody and a rhodamine-conjugated goat anti-mouse secondary antibody. Overlays (right) show extensive colocalization of both ETA-GFP (C) and ETB-GFP (F) with Rab5 in early endosomes.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The purpose of this study was to investigate the mechanisms of internalization and intracellular trafficking of the ETA and ETB receptors. We report for the first time the involvement of arrestin and dynamin in the regulation of the ET receptors, and we describe the previously unknown intracellular routes of agonist-stimulated ETA and ETB receptors.

Both ETA and ETB receptors have been shown to undergo agonist-dependent phosphorylation catalyzed by GRK. In transfected HEK293 cells with overexpression of either beta ARK1 (GRK2), beta ARK2 (GRK3), or GRK5, all of the kinases have been shown to phosphorylate agonist-activated ET receptors (20). However, the specificity of the different GRK isoforms as to the substrates ETA and ETB is not known. In the present study, increased levels of beta ARK1 did not augment internalization of the ET receptors. However, beta ARK1-CT substantially inhibited internalization of the ETA receptor and to a lesser degree that of ETB, demonstrating that at least ETA receptor internalization is a beta ARK1-mediated process. The less pronounced effect of beta ARK1-CT on internalization of ETB may be due to phosphorylation of the ETB receptor by other endogenously expressed receptor kinases in the CHO cells not subject to competitive inhibition by beta ARK1-CT. The lack of effect of beta ARK1 wild type overexpression on internalization of the ETA receptor indicates that beta ARK1-mediated phosphorylation is not rate-limiting for endocytosis in CHO cells, a cell line that displays substantial levels of endogenously expressed beta ARK1. Although both receptor subtypes have cytoplasmic tails containing several serine and threonine residues (40, 41), only ETB has motifs similar to those previously demonstrated to be phosphorylated by GRK (42).

The ability of the beta -arrestin-1 V53D and beta -arrestin-2 V54D mutants to inhibit both ETA and ETB receptor internalization provides strong evidence that arrestin isoforms regulate both receptor subtypes. These mutant arrestins compete with endogenous arrestins in the cell by binding to clathrin, but they display reduced affinity for the receptor (14). Our data therefore demonstrate that the endogenous arrestins of the CHO cells contribute to ET receptor endocytosis. However, our data do not indicate the specific isoforms of arrestin involved in ET receptor regulation. Arrestin appears to be a rate-limiting factor for internalization, since overexpression of beta -arrestin-1 or beta -arrestin-2 resulted in a significant increase in the rates of internalization of both the ETA and the ETB receptors. Consistent with these data, it has earlier been demonstrated that arrestin binding is rate-limiting in the process of desensitization of the GPCR rhodopsin in Drosophila (43).

As shown, the GTPase-deficient mutant dynamin K44A significantly impaired ET receptor internalization. The involvement of dynamin is considered to be a strong indicator for a clathrin-dependent mechanism of internalization, although evidence also indicates that dynamin may regulate other mechanisms of endocytosis (44). However, our observations that potassium depletion of CHO cells (31) or pretreatment in hyperosmotic sucrose (30) both impaired internalization of ETA and ETB receptors provide further evidence for the involvement of clathrin-coated pits in endocytosis of these receptors. Previously, Chun et al. (45) have proposed a role for caveolae in ET receptor signaling and regulation, based on colocalization of ETA receptors and caveolin in COS cells as assessed by immunofluorescence. Although other GPCRs and related proteins involved in signal transduction have also been shown to be localized to caveolae (46, 47), the role of these subcellular structures in GPCR internalization is still poorly understood.

Recently, it was shown that although internalized beta 2 adrenergic receptor colocalizes with the transferrin receptor in early endosomes, the receptors were located to different subpopulations of clathrin-coated vesicles at earlier stages of endocytosis (48). We have not investigated whether the ETA and ETB receptors follow the same initial steps of endocytosis as the transferrin receptor, but since both subtypes depend on classical regulators of GPCRs, it is likely that they follow the same pathway as the beta 2 adrenergic receptor into early endosomes. The classical early endosome, also called the sorting endosome, is a tubulovesicular structure where membrane proteins destined for degradation are sorted away from recycling proteins and packed into multivesicular bodies for further transport. Membrane proteins destined for recycling are, on the other hand, rapidly transported from the sorting endosome to the pericentriolar recycling compartment and are subsequently directed back to the plasma membrane (49, 50). We found that the transport routes of both the ETA and the ETB receptors go through early endosomes, which is probably the final common compartment of the two receptor subtypes.

The information for receptor targeting either to recycling or to lysosomal degradation may reside in the cytoplasmic tail of the receptors (51). Furthermore, data from a recent report suggest that the presence of a cluster of serines in the tail of a GPCR appears to mediate stable binding of arrestin and dictate internalized receptors to lysosomes (52). According to the hypothesis presented in the latter report, configurations of the cytoplasmic tail causing less stable binding to arrestin lead to recycling and resensitization of the receptor. Interestingly, the ETB receptor has a C-terminal cluster of serines, which is not present in the tail of the ETA receptor. Lysosomal targeting of the ETB receptor could therefore be due to more stable interactions with arrestin, while less stable binding to the tail of the ETA receptor may lead this subtype to the recycling pathway. Consistent with this hypothesis, it has been demonstrated that the ETA receptor is not able to translocate beta -arrestins to intracellular compartments (53). The hypothesis that arrestin may target GPCRs to lysosomes is also supported by ultrastructural data showing subcellular location of beta -arrestin in multivesicular bodies (24).

ET-1 has been shown to dissociate very slowly from the ET receptors, even at the low pH values corresponding to those of endosomes (pH 5.5-6.0) and lysosomes (pH 4.4-5.5) (21, 54, 55). Indeed, ET-1 has been reported to remain bound to the ETA receptor after internalization (21). Thus, it has been hypothesized that ligand-occupied ETA receptors may continue to activate the G protein after endocytosis. In this respect, internalization of GPCRs has been reported to be a prerequisite for transactivation of the epidermal growth factor receptor (56). However, rapid receptor endocytosis, resensitization, and recycling back to the plasma membrane in order to initiate repeated cycles of signaling may also provide the basis for a prolonged signal response. In fact, several reports have shown that receptor internalization is obligatory for resensitization of GPCRs (57-59). Thus, the evidence provided in this report that ETA receptors are targeted to recycling may explain the long lasting signal response observed through this receptor subtype.

ET-1 binds almost irreversibly to the ETB receptor at physiological conditions (55). Thus, in context of our findings, direct transport of receptor-associated ET-1 to lysosomes for degradation could serve as the mechanism for clearance of plasma ET-1 via the ETB receptor subtype. The high affinity between ETB receptor and ET-1 ensures efficient capture of ET-1 at the low (picomolar) levels in plasma but also implicates that the receptor is simultaneously sacrificed in the clearance process. This hypothesis correlates, however, well with the transient nature of ETB receptor-mediated signaling. Moreover, we have shown in the present study that the reappearance of ETB receptors at the plasma membrane is sensitive to cycloheximide. This implicates that the supply of de novo synthesized receptor molecules to the cell surface would be a limiting factor for the ability of ETB receptors to mediate efficient clearance of plasma ET-1.

In conclusion, the present study demonstrates that the ET receptor subtypes ETA and ETB are rapidly internalized in an agonist-dependent manner, a process that appears to depend on GRK, arrestin, dynamin, and clathrin. Furthermore, we have demonstrated that internalized ETA and ETB receptors both enter Rab5 positive early endosomes (sorting endosomes). However, the two receptor subtypes are subsequently targeted to different intracellular fates. While the ETA receptor follows a recycling pathway through the pericentriolar recycling compartment and reappears at the plasma membrane, the ETB receptor is directed to lysosomes for degradation. Based on the data presented in this study, we propose a model for the intracellular trafficking pathways of the ET receptors, which is illustrated in the schematic diagram of Fig. 9. The distinct intracellular routes of ETA and ETB may explain the characteristic physiological responses mediated by these receptors. Thus, the rapid recycling of ETA may provide a basis for the prolonged contractile response mediated through this receptor, whereas lysosomal targeting of ETB supports current evidence suggesting a role for this receptor in clearance of ET from the circulation. The aim of future studies will be to delineate the mechanisms of the sorting process in early endosomes where the intracellular routes of the two receptor subtypes separate.


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 9.   Model for regulation and intracellular trafficking of the ET receptors. Based on the data of the present study, a model for regulation and intracellular trafficking of the ETA and ETB receptors is proposed. As indicated in the diagram, both ETA and ETB are rapidly internalized upon agonist stimulation, a process that depends on GRK, arrestin, dynamin, and clathrin. Internalized ETA and ETB are subsequently directed to Rab5 positive early endosomes (sorting endosomes). However, from this location, the two receptor subtypes are targeted to different intracellular fates. Whereas the ETA receptor is directed to the pericentriolar recycling compartment and subsequently reappears at the plasma membrane, the ETB receptor is directed to lysosomes for degradation.


    FOOTNOTES

* This work was supported by the MSD-Medinnova Cardiovascular Research Fund and grants from the National Research Council and the Norwegian Council on Cardiovascular Diseases.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed: Inst. of Surgical Research/MSD-Cardiovascular Research Center, The National Hospital, 32 Pilestredet, N-0027 Oslo, Norway. Tel.: 47-22868522; Fax: 47-22111987; E-mail: havarda@rh.uio.no.

Published, JBC Papers in Press, March 30, 2000, DOI 10.1074/jbc.M000142200

    ABBREVIATIONS

The abbreviations used are: ET, endothelin; GPCR, G protein-coupled receptor; GRK, G protein-coupled receptor kinase; CHO, Chinese hamster ovary; GFP, green fluorescent protein; beta ARK, beta -adrenergic receptor kinase; Tf, transferrin; TfR, transferrin receptor; Rh-Tf, tetramethylrhodamine-labeled transferrin; WT, wild type; BSA, bovine serum albumin; PBS, phosphate-buffered saline.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Yanagisawa, M., Kurihara, H., Kimura, S., Tomobe, Y., Kobayashi, M., Mitsui, Y., Yazaki, Y., Goto, K., and Masaki, T. (1988) Nature 332, 411-415
2. Sakurai, T., Yanagisawa, M., and Masaki, T. (1992) Trends Pharmacol. Sci. 13, 103-108
3. Cramer, H., Muller-Esterl, W., and Schroeder, C. (1997) Biochemistry 36, 13325-13332
4. Clozel, M., Gray, G. A., Breu, V., Loffler, B. M., and Osterwalder, R. (1992) Biochem. Biophys. Res. Commun. 186, 867-873
5. Moreland, S., McMullen, D. M., Delaney, C. L., Lee, V. G., and Hunt, J. T. (1992) Biochem. Biophys. Res. Commun. 184, 100-106
6. Yanagisawa, M., and Masaki, T. (1989) Biochem. Pharmacol. 38, 1877-1883
7. Dupuis, J., Goresky, C. A., and Fournier, A. (1996) J. Appl. Phys. 81, 1510-1515
8. Fukuroda, T., Fujikawa, T., Ozaki, S., Ishikawa, K., Yano, M., and Nishikibe, M. (1994) Biochem. Biophys. Res. Commun. 199, 1461-1465
9. Kobayshi, T., Miyauchi, T., Sakai, S., Maeda, S., Yamaguchi, I., Goto, K., and Sugishita, Y. (1998) Life Sci. 62, 185-193
10. Yu, S. S., Lefkowitz, R. J., and Hausdorff, W. P. (1993) J. Biol. Chem. 268, 337-341
11. Krueger, K. M., Daaka, Y., Pitcher, J. A., and Lefkowitz, R. J. (1997) J. Biol. Chem. 272, 5-8
12. Pippig, S., Andexinger, S., and Lohse, M. J. (1995) Mol. Pharmacol. 47, 666-676
13. Freedman, N. J., and Lefkowitz, R. J. (1996) Rec. Prog. Horm. Res. 51, 319-353
14. Ferguson, S. S., Downey, W. E., III, Colapietro, A. M., Barak, L. S., Menard, L., and Caron, M. G. (1996) Science 271, 363-366
15. Goodman, O. B., Jr., Krupnick, J. G., Santini, F., Gurevich, V. V., Penn, R. B., Gagnon, A. W., Keen, J. H., and Benovic, J. L. (1996) Nature 383, 447-450
16. von Zastrow, M., and Kobilka, B. K. (1992) J. Biol. Chem. 267, 3530-3538
17. Lefkowitz, R. J. (1998) J. Biol. Chem. 273, 18677-18680
18. Ferguson, S. S., Zhang, J., Barak, L. S., and Caron, M. G. (1998) Life Sci. 62, 1561-1565
19. Cyr, C. R., Rudy, B., and Kris, R. M. (1993) J. Biol. Chem. 268, 26071-26074
20. Freedman, N. J., Ament, A. S., Oppermann, M., Stoffel, R. H., Exum, S. T., and Lefkowitz, R. J. (1997) J. Biol. Chem. 272, 17734-17743
21. Chun, M., Lin, H. Y., Henis, Y. I., and Lodish, H. F. (1995) J. Biol. Chem. 270, 10855-10860
22. Sakamoto, A., Yanagisawa, M., Sawamura, T., Enoki, T., Ohtani, T., Sakurai, T., Nakao, K., Toyo-oka, T., and Masaki, T. (1993) J. Biol. Chem. 268, 8547-8553
23. van der Bliek, A. M., Redelmeier, T. E., Damke, H., Tisdale, E. J., Meyerowitz, E. M., and Schmid, S. L. (1993) J. Cell Biol. 122, 553-563
24. Attramadal, H., Arriza, J. L., Aoki, C., Dawson, T. M., Codina, J., Kwatra, M. M., Snyder, S. H., Caron, M. G., and Lefkowitz, R. J. (1992) J. Biol. Chem. 267, 17882-17890
25. Stenmark, H., Bucci, C., and Zerial, M. (1995) Methods Enzymol. 257, 155-164
26. Elshourbagy, N. A., Korman, D. R., Wu, H. L., Sylvester, D. R., Lee, J. A., Nuthalaganti, P., Bergsma, D. J., Kumar, C. S., and Nambi, P. (1993) J. Biol. Chem. 268, 3873-3879
27. Daaka, Y., Pitcher, J. A., Richardson, M., Stoffel, R. H., Robishaw, J. D., and Lefkowitz, R. J. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 2180-2185
28. Laporte, S. A., Oakley, R. H., Zhang, J., Holt, J. A., Ferguson, S. S., Caron, M. G., and Barak, L. S. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 3712-3717
29. Damke, H., Baba, T., Warnock, D. E., and Schmid, S. L. (1994) J. Cell Biol. 127, 915-934
30. Heuser, J. E., and Anderson, R. G. (1989) J. Cell Biol. 108, 389-400
31. Larkin, J. M., Brown, M. S., Goldstein, J. L., and Anderson, R. G. (1983) Cell 33, 273-285
32. Okamoto, Y., Ninomiya, H., Tanioka, M., Sakamoto, A., Miwa, S., and Masaki, T. (1997) J. Biol. Chem. 272, 21589-21596
33. Yamashiro, D. J., Tycko, B., Fluss, S. R., and Maxfield, F. R. (1984) Cell 37, 789-800
34. Mayor, S., Presley, J. F., and Maxfield, F. R. (1993) J. Cell Biol. 121, 1257-1269
35. Donaldson, J. G., Kahn, R. A., Lippincott-Schwartz, J., and Klausner, R. D. (1991) Science 254, 1197-1199
36. Presley, J. F., Mayor, S., Dunn, K. W., Johnson, L. S., McGraw, T. E., and Maxfield, F. R. (1993) J. Cell Biol. 122, 1231-1241
37. Olkkonen, V. M., and Stenmark, H. (1997) Int. Rev. Cytol. 176, 1-85
38. Gorvel, J. P., Chavrier, P., Zerial, M., and Gruenberg, J. (1991) Cell 64, 915-925
39. Stenmark, H., Parton, R. G., Steele-Mortimer, O., Lutcke, A., Gruenberg, J., and Zerial, M. (1994) EMBO J. 13, 1287-1296
40. Sakamoto, A., Yanagisawa, M., Sakurai, T., Takuwa, Y., Yanagisawa, H., and Masaki, T. (1991) Biochem. Biophys. Res. Commun. 178, 656-663
41. Hosoda, K., Nakao, K., Hiroshi, A., Suga, S., Ogawa, Y., Mukoyama, M., Shirakami, G., Saito, Y., Nakanishi, S., and Imura, H. (1991) FEBS Lett. 287, 23-26
42. Fredericks, Z. L., Pitcher, J. A., and Lefkowitz, R. J. (1996) J. Biol. Chem. 271, 13796-13803
43. Ranganathan, R., and Stevens, C. F. (1995) Cell 81, 841-848
44. Oh, P., McIntosh, D. P., and Schnitzer, J. E. (1998) J. Cell Biol. 141, 101-114
45. Chun, M., Liyanage, U. K., Lisanti, M. P., and Lodish, H. F. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 11728-11732
46. Roettger, B. F., Rentsch, R. U., Pinon, D., Holicky, E., Hadac, E., Larkin, J. M., and Miller, L. J. (1995) J. Cell Biol. 128, 1029-1041
47. Raposo, G., Dunia, I., Marullo, S., Andre, C., Guillet, J. G., Strosberg, A. D., Benedetti, E. L., and Hoebeke, J. (1987) Biol. Cell 60, 117-123
48. Cao, T. T., Mays, R. W., and von Zastrow, M. (1998) J. Biol. Chem. 273, 24592-24602
49. Dunn, K. W., McGraw, T. E., and Maxfield, F. R. (1989) J. Cell Biol. 109, 3303-3314
50. Ghosh, R. N., and Maxfield, F. R. (1995) J. Cell Biol. 128, 549-561
51. Trejo, J., and Coughlin, S. R. (1999) J. Biol. Chem. 274, 2216-2224
52. Oakley, R. H., Laporte, S. A., Holt, J. A., Barak, L. S., and Caron, M. G. (1999) J. Biol. Chem. 274, 32248-32257
53. Zhang, J., Barak, L. S., Anborgh, P. H., Laporte, S. A., Caron, M. G., and Ferguson, S. S. (1999) J. Biol. Chem. 274, 10999-11006
54. Mellman, I. (1992) J. Exp. Biol. 172, 39-45
55. Takasuka, T., Adachi, M., Miyamoto, C., Furuichi, Y., and Watanabe, T. (1992) J. Biochem. (Tokyo) 112, 396-400